Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma.

Marachelian A, Shimada H, Sano H, Jackson H, Stein J, Sposto R, Matthay KK, Baker D, Villablanca JG.

Pediatr Blood Cancer. 2012 May;58(5):675-81.

PMID:
22493777
2.

Neuroblastoma in adults and adolescents: an indolent course with poor survival.

Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK.

Cancer. 1997 May 15;79(10):2028-35.

PMID:
9149032
3.

Neuroblastoma: treatment outcome after incomplete resection of primary tumors.

Moon SB, Park KW, Jung SE, Youn WJ.

Pediatr Surg Int. 2009 Sep;25(9):789-93. doi: 10.1007/s00383-009-2417-8. Epub 2009 Jul 21.

PMID:
19629500
4.

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.

Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK.

J Clin Oncol. 2005 Sep 20;23(27):6474-80. Epub 2005 Aug 22.

PMID:
16116154
5.

Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.

Okazaki T, Kohno S, Mimaya J, Hasegawa S, Urushihara N, Yoshida A, Kawano S, Kusafuka J, Horikoshi Y, Takashima Y, Aoki K, Hamazaki M.

Pediatr Surg Int. 2004 Jan;20(1):27-32. Epub 2003 Dec 19.

PMID:
14689211
6.

Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.

Cheung NK, Kushner BH, LaQuaglia MP, Kramer K, Ambros P, Ambros I, Ladanyi M, Eddy J, Bonilla MA, Gerald W.

Eur J Cancer. 1997 Oct;33(12):2117-20.

PMID:
9516865
7.

Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants.

Marcus KJ, Shamberger R, Litman H, von Allmen D, Grupp SA, Nancarrow CM, Goldwein J, Grier HE, Diller L.

J Pediatr Hematol Oncol. 2003 Dec;25(12):934-40.

PMID:
14663275
8.

Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease.

Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F.

Strahlenther Onkol. 2006 Jul;182(7):389-94.

PMID:
16826357
9.

Neuroblastoma.

Meir HM, Balawi I, Nayel H, Yousef MK, Badawood S, Al-Mobarak M.

Saudi Med J. 2001 Aug;22(8):674-80.

PMID:
11573111
10.

Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.

Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H.

Nuklearmedizin. 2006;45(4):145-51; quiz N39-40.

PMID:
16964339
11.

Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma.

Chamberlain RS, Quinones R, Dinndorf P, Movassaghi N, Goodstein M, Newman K.

Ann Surg Oncol. 1995 Mar;2(2):93-100.

PMID:
7728576
12.

Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results.

Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, Haase GM, Stram DO, Seeger RC.

Eur J Cancer. 1995;31A(4):572-5.

PMID:
7576971
13.

Complete resection is not required in patients with neuroblastoma under 1 year of age.

Kaneko M, Iwakawa M, Ikebukuro K, Ohkawa H.

J Pediatr Surg. 1998 Nov;33(11):1690-4.

PMID:
9856897
14.

Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL.

J Clin Oncol. 2005 Sep 20;23(27):6459-65. Epub 2005 Aug 22.

PMID:
16116153
15.

[Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].

Ladenstein R, Ambros PF, Urban C, Ambros IM, Fink FM, Zoubek A, Grienberger H, Schmitt K, Kerbl R, Horcher E, Amann G, Höfler G, Heinzl H, Gadner H, Mutz I.

Klin Padiatr. 1996 Jul-Aug;208(4):210-20. German.

PMID:
8926686
16.

Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.

Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC.

J Natl Cancer Inst. 1995 Oct 4;87(19):1470-6.

PMID:
7674334
17.

Pelvic neuroblastoma: low mortality and high morbidity.

Cruccetti A, Kiely EM, Spitz L, Drake DP, Pritchard J, Pierro A.

J Pediatr Surg. 2000 May;35(5):724-8.

PMID:
10813335
18.

Neuroblastoma in Turkish children: experience of a single center.

Aydn GB, Kutluk MT, Yalçn B, Büyükpamukçu M, Kale G, Varan A, Akyüz C, Senocak ME, Büyükpamukçu N.

J Pediatr Hematol Oncol. 2009 Jul;31(7):471-80. doi: 10.1097/MPH.0b013e3181a6dea4.

PMID:
19564739
19.

The role of surgery in stage IV neuroblastoma.

Castel V, Tovar JA, Costa E, Cuadros J, Ruiz A, Rollan V, Ruiz-Jimenez JI, Perez-Hernández R, Cañete A.

J Pediatr Surg. 2002 Nov;37(11):1574-8.

PMID:
12407542
20.

Risk-based management: current concepts of treating malignant solid tumors of childhood.

Grosfeld JL.

J Am Coll Surg. 1999 Oct;189(4):407-25. Review.

PMID:
10509467

Supplemental Content

Support Center